R&D JP Morgan 2024 – Trevor Martin Editor-in-chief Jonah Comstock caught up with Trevor Martin, co-founder and CEO of Mammoth Biosciences
R&D JP Morgan 2024 – Katherine Stueland Diagnostics can be a neglected part of the treatment paradigm, but it’s hugely important for connecting patients with the right treatments.
R&D JP Morgan 2024 – Frank Gleeson In this brief dispatch from JP Morgan, Editor in Chief Jonah Comstock grabs a few minutes with Frank Gleeson, CEO of Satellos Bioscience.
R&D JP Morgan 2024 – Jen Nwankwo While 2023 may have been the year of AI for the consumer consciousness, for companies using the technology in a focused way in drug development it was just another year of learning and adva
R&D JP Morgan 2024 – Graham Heap Just over a year ago, Takeda acquired a promising immunotherapy candidate, TAK-279, from Boston-based Nimbus Therapeutics.
News Third death reported with a Sarepta gene therapy A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles being faced by the company.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face